导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.79% | 3617/4773 |
| 近一周 | -1.84% | 784/5462 |
| 近一月 | -2.37% | 1251/5421 |
| 近一季 | -6.01% | 1964/5209 |
| 近半年 | -6.42% | 3082/4920 |
| 近一年 | -8.94% | 3288/4366 |
| 近两年 | 35.07% | 2094/2954 |
| 近三年 | 17.82% | 1556/2253 |
| 成立以来 | 4.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.32% 4096/4961 |
2.76% 2962/5312 |
- - |
- - |
| 2025 | 22.15% 1993/4813 |
4.95% 859/3635 |
4.19% 835/4076 |
14.09% 2951/4524 |
-2.08% 3084/4813 |
| 2024 | 14.06% 1079/3463 |
-3.14% 1472/2808 |
2.65% 325/3014 |
18.95% 906/3129 |
-3.55% 2363/3463 |
| 2023 | -15.44% 1649/2656 |
0.70% 1712/2280 |
-2.87% 697/2385 |
-8.36% 1694/2515 |
-5.66% 1447/2655 |
| 2022 | -14.29% 362/2207 |
-12.81% 659/1919 |
5.11% 939/2016 |
-15.83% 1348/2113 |
11.12% 153/2208 |
| 2021 | -13.98% 1141/1822 |
0.30% 304/1255 |
-0.76% 1149/1330 |
-11.61% 1273/1466 |
-2.22% 1405/1822 |
| 2020 | 18.48% 744/1250 |
-11.22% 824/1028 |
13.78% 593/1067 |
5.48% 915/1164 |
11.20% 556/1184 |
| 2019 | - - |
- - |
- - |
- - |
2.91% 850/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 方正富邦大湾区综指(LOF) VS. 长安沪深300非周期A(740101) |